MustBio introduced a novel aPD-L1 x CD3 at the American Association for Cancer Research (AACR) Annual Meeting 2023. (Biospectator, 2023.05.12)
- Date2023-05-12
- View1529
MustBio presented results on MB101, a PD-L1 x CD3 bispecific antibody and MB201, a PD-L1 x IL-2 fusion protein at the American Association for Cancer Research held in Orlando, USA.1
